Disney's (NYSE:DIS) Oz: The Great and Powerful scored the top spot in weekend box office sales by a mile, easily outpacing its nearest competitors with domestic revenue of more than $80 million, according to data compiled by Rentrak. Oz pulled in around $150 million worldwide in its debut weekend in theaters, according to data released by media measurement company Rentrak.
Disney's take on the Wizard of Oz scored a box office hit after a strong promotional campaign and a budget that Box Office Mojo puts at more than $200 million. The film, a prequel to the original classic that tells the story of the titular wizard in the land of Oz, delivered a punch for the movie industry after a lackluster start to the year. Box office sales have fallen 12.5% year-over-year so far in 2013, a Hollywood.com analyst told CBS News.
Jack the Giant Slayer, the folk story retelling from Time Warner (NYSE:TWX) subsidiary Warner Brothers, managed to squeeze out $10 million in domestic sales to take the distant runner-up spot in its second weekend in theaters. (The previous weekend, when Jack ranked No. 1, it tallied $27 million at the box office.) Hansel and Gretel: Witch Hunters, another folk story reimagining from Viacom (NASDAQ:VIA) subsidiary Paramount Pictures, ranked third internationally with weekend revenue of $11.4 million in the most recent weekend.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Walt Disney. The Motley Fool owns shares of Walt Disney. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Hate Checking Your Portfolio? Try These 2 High-Yield Stocks
If you agree with the notion that boring is good, then check out this energy company and this petroleum pipeline operator.
What Is a Family Limited Partnership?
Want a way to protect your family's wealth from the IRS? Enter the FLP.
Will This Tiny Biotech Be Celgene's Next Takeover Target?
Depending on data later this year, Celgene may want to buy this collaboration partner.